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Case Report
Bisphosphonate-related bilateral atypical 
femoral fractures – be aware and beware
Abstract
Although bisphosphonates have a well established 
therapeutic role in the prevention of osteoporosis-related 
fractures, several reports published over the past 5-6 years 
suggest a possible causative relationship between long-
term use of bisphosphonates and development of ‘atypical’ 
subtrochanteric and femoral diaphyseal fractures.  A high level 
of clinical suspicion and prompt imaging when these patients 
present with groin/thigh pain should lead to a timely diagnosis. 
Appropriate elective management to mitigate against the 
increased risks of these fractures becoming complete could 
then be instituted.  We present a case of complete bilateral 
atypical subtrochanteric fractures in a patient on long-term 
bisphosphonates for osteoporosis.  Our objective is to highlight 
the fracture risk of this patient population; present the current 
knowledge; and discuss the dilemmas in management of both 
femora.
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Bisphosphonates have a well established therapeutic role 
in the prevention of osteoporosis-related fractures.  They have 
been shown to reduce the risk of insufficiency fractures of the 
hip and spine in post-menopausal, osteoporotic females.1,2,3,4 
Over recent years, reports have suggested a direct 
relationship between long-term use of bisphosphonates and 
the development of subtrochanteric and femoral diaphyseal 
fractures with an ‘atypical’ site and configuration.  The exact 
mechanism underlying this apparent increase in fracture risk 
is still unclear.  
We present a case of bilateral atypical complete subtro-
chanteric fractures in a patient on long-term bisphosphonates 
for osteoporosis.
Case report 
A 60 year old lady was initially diagnosed with osteoporosis 
in 2005.  She had no significant past medical history and 
apart from hormone replacement therapy (HRT) was not on 
glucocorticoid treatment or any other prescribed medication. 
She was a non-smoker and drank very little alcohol.  Her 
bone mineral content at the time was just below the fracture 
threshold and since she had just stopped her HRT she was 
offered prophylactic bisphosphonate treatment.  She initially 
opted to postpone therapy but suffered a stress fracture of her 
third metatarsal in 2006 and was started on oral risedronate 
35mg weekly.  A follow up bone density scan in 2007 showed 
an improvement in bone density of both the femoral neck 
and lumbar spine (T-score -1.8 (femur) and -2.1 (L2)). 
Bisphosphonate treatment was changed to alendronate in 2008 
and she carried on taking this regularly.
In February 2010 she visited her general practitioner 
complaining of a 3 month history of left hip pain and stiffness 
and was referred for a plain radiograph of her pelvis (Fig.1).  This 
showed mild focal thickening of the proximal subtrochanteric 
lateral cortices bilaterally particularly on the left.  These findings 
were not appreciated at the time.  A few months later, in May 
2010, the patient tripped down two steps and sustained an 
atypical subtrochanteric fracture of her left femur (Fig. 2) which 
was treated with a proximal femoral nail antirotation (PFNA) 
procedure.  Early post-operative imaging (Fig. 3) clearly shows 
that the fracture had occurred through the area of previously 
demonstrated cortical beaking.  
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A follow-up pelvic radiograph in September 2010, 4 
months following injury, showed two interesting findings (Fig. 
4).  Apart from showing that fracture healing was progressing 
satisfactorily, it also showed that the previously noted right 
lateral cortical beaking had increased in size since injury.  A 
fracture through the left lateral cortex a few centimetres distal 
to the first fracture was noted.  Again we note that, most likely 
due to lack of awareness, the right femoral findings were not 
acted upon.
Just three weeks later, in October whilst out shopping, she 
turned awkwardly and suffered yet another atypical complete 
subtrochanteric fracture of the right femur (Fig. 5) which was 
again managed with a PFNA procedure (Fig. 6).  The right 
fracture was again noted to run through the site of previously 
seen cortical thickening.  In hindsight, the patient did recall 
that whilst recovering from her left hip operation and using 
crutches, she was aware of some pain in her right hip which 
she had dismissed.
Subsequent investigations including serum parathyroid 
hormone (PTH), serum vitamin D, skeletal survey, chest x-ray, 
breast screening and a myeloma screen were all normal. She 
initially continued on alendronate until she read an article in 
Figure 1:.  Antero-posterior (AP) plain 
pelvic radiograph (February 2010) 
showing mild focal thickening of the 
proximal subtrochanteric lateral cortices 
of both femora (arrows) more so on the 
left.
Figure 2: AP pelvic radiograph (May 
2010) showing a complete atypical 
subtrochanteric fracture of the left 
femur.  The previously noted right-sided 
beaking is not visible on this projection.
Figure 3:  Postoperative AP plain 
radiograph of the left femur showing 
the PFNA in situ and confirming that 
the fracture had occurred through the 
area of previously demonstrated cortical 
beaking (arrow).
the local newspaper about atypical femoral fractures, following 
which she stopped alendronate treatment and continued 
vitamin D and calcium supplements.  The patient was then 
transferred to our hospital’s Metabolic Disorders Department. 
Discussion
The lifetime risk of developing an osteoporotic fracture 
is approximately 50% in females and 25% in males.2  
Subtrochanteric and diaphyseal fractures of the femur account 
for 7-10% of all hip and femoral shaft fractures.2,3  Having 
excluded high-impact trauma and periprosthetic fractures, 
the ‘atypical’ type accounts for just 1.1–1.7% of all femoral 
fractures.  These fractures have been labelled ‘atypical’ due to 
their uncommon site and configuration (Table 1), and have been 
attributed to bisphosphonates use.  Atypical fractures appear 
to be commoner in patients who have been on bisphosphonate 
therapy, more so in patients who have been treated for over 3 
years (median 7 years).  They have, however, also been described 
in patients who have not been exposed to bisphosphonates and 
the definitive causal relationship is yet to be proven.3,4,5
Bisphosphonates are thought to influence bone metabolism 
in many ways.  The organic matrix of bone is the prime 
Figure 4: AP pelvic radiograph 
(September 2010) showing that the 
previously noted lateral cortical 
beaking of the right femur had 
increased in size since injury (arrow).  
A fracture through the left lateral cortex 
a few centimetres distal to the first 
fracture was also noted (arrowhead).  
Figure 5:  AP pelvic radiograph 
(October 2010) showing the second 
complete atypical subtrochanteric 
fracture of the contralateral right femur. 
Figure 6:.  Postoperative AP pelvic 
radiograph (October 2010) showing 
bilateral PFNA in situ again confirming 
that the fracture had occurred through 
the area of previously demonstrated 
cortical beaking (arrow).
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trauma, fracture configuration, prodromal pain, bilaterality, 
lateral cortical thickening and generalised diaphyseal cortical 
thickening had been previously documented as typical of these 
fractures.1,2,4  Prodromal pain has been reported in 70-75% of 
cases2,3 and bilateral fractures are seen in 28%.3  Femoral neck 
fractures, intertrochanteric fractures with spiral subtrochanteric 
extension, periprosthetic fractures and pathological fractures 
associated with primary or secondary bone tumours have been 
specifically excluded.3  These fractures should be differentiated 
from Looser zones and sports-related stress fractures both of 
which typically involve the medial cortex.1,3
A recent prospective Study of Osteoporotic Fractures (SOF) 
has shown that the incidence of subtrochanteric fractures is very 
low (3/10000 person-years) compared to an overall incidence 
of hip fractures of 103/10000 person-years.7  Screening of 
all patients on long-term bisphosphonates in search of early 
features of atypical fractures is not, therefore, cost-effective 
and is not thought to be warranted.1  It is however advised that 
any patient, who is known to be on long-term bisphosphonates 
therapy, and presents with groin/hip pain should be imaged.1,3 
Conventional plain film imaging is the first line of investigation. 
Anteroposterior and lateral projections of the proximal femora 
down to the distal femoral metaphyses should be obtained. 
Typical features of incomplete atypical fractures may initially 
include a focal thickening of the lateral cortex resulting in what 
has been described as ‘beaking’ or ‘flaring’.  A transverse or 
mildly oblique fracture line may subsequently appear typically 
starting at the lateral cortex and progressing medially.   When the 
fracture becomes ‘complete’ it may be associated with a medial 
cortical spike.3  More advanced imaging modalities should be 
contributor to strength and bisphosphonates have been shown 
to have both positive and negative effects on matrix by affecting 
the maturation process of collagen.  Bisphosphonates are known 
to reduce bone turnover through their effect on osteoclasts and 
secondarily osteoblasts, which in turn causes an increase in 
overall bone mineralisation resulting in increased bone strength. 
Paradoxically, however, reduction of bone turnover also results 
in accumulation of advanced glycation end products (AGEs) 
which in turn are associated with rendering bone increasingly 
brittle.  Bisphosphonates also play a role in suppressing excessive 
bone remodelling which would increase bone fragility.  Bone 
remodelling is also responsible, however, for the removal of 
microdamage that accumulates with use, and its suppression by 
bisphosphonates can lead to accumulation of tiny cracks which 
could weaken the bone structure.  It is currently thought that a 
combination of these factors may be involved in the development 
of atypical femoral fractures.  The clinical importance of the 
side-effects of bisphosphonates on human bone is not entirely 
clear.  The existing published reports of these atypical fractures 
in patients exposed to bisphosphonates have merely highlighted 
a potential link between the two and more scientific research is 
required to confirm this.2,3,4,6 
Shane et al. have defined a list of major and minor features 
for the diagnosis of complete and incomplete atypical fractures 
of the femur in an attempt to ensure that future studies report 
on the exact same condition (Table 1).  They claim that all major 
features must be present to qualify a fracture as ‘atypical’, as 
opposed to the more common types of hip and femoral shaft 
fractures.  Minor features may or may not be present.3  Most of the 
described features, including the location, absence of significant 
Major featuresb
• Located anywhere along the femur from just distal to the lesser trochanter to just proximal to the    
supracondylar flare
• Associated with no or minimal trauma as in a fall from standing height or less
• Transverse or short oblique configuration
• Not comminuted
• Complete fractures extend through both cortices and may be associated with a medial spike; 
 Incomplete fractures involve only the lateral cortex
Minor features
• Localised periosteal reaction of lateral cortex (often referred to in the literature as beaking or flaring)
• Generalised increase in cortical thickness of the diaphysis
• Prodromal symptoms such as dull or aching pain in the groin or thigh
• Bilateral fractures and symptoms
• Delayed healing
• Comorbid conditions e.g. vitamin D deficiency, rheumatoid arthritis
• Use of pharmaceutical agents e.g. bisphosphonates, glucocorticoids, proton pump inhibitors
aSpecifically excluded are fractures of the femoral neck, intertrochanteric fractures with spiral subtrochanteric extension, pathologic
fractures associated with primary or metastatic bone tumours, and periprosthetic fractures.
bAll major features are required to satisfy the case definition of atypical femoral fracture.  None of the minor features are required but
vsometimes have been associated with these fractures. 
From Shane et al. J Bone Miner Res. 20103
Table 1: Atypical femoral fracture: major and minor featuresa
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considered, in patients with a history of prodromal thigh or hip 
pain, when plain x-rays are normal or inconclusive.  An Isotope 
bone scan may be utilised and, if positive, will show an intense 
focus of uptake at the fracture site with a more subtle uptake 
zone surrounding it.  The advantages of radionuclide imaging 
are the ability to evaluate both thighs, early diagnosis of bilateral 
fractures and demonstration of otherwise occult fractures.  
Magnetic Resonance Imaging (MRI) can similarly detect 
the focal cortical thickening which is typically of low signal on 
both T1- and T2-weighted sequences, as well as the surrounding 
marrow oedema which is of diffuse intermediate/low signal 
on T1-weighted sequences and of intermediate/high signal on 
fluid sensitive sequences such as STIR and T2-weighted fat 
suppressed sequences.  The fracture-line arising in the lateral 
cortex may also be visible on certain occasions.  Multi-Detector 
Computerised Tomography (MDCT) can also be used to evaluate 
the bony architecture in more detail and may demonstrate the 
focal lateral cortical thickening and the lucent fracture line 
arising laterally.3
Subtrochanteric complete fractures have a significant effect 
on patients’ morbidity and mortality.  Two years post-injury, up 
to 50% of patients had still not returned to their premorbid state 
of social well-being.  A mortality rate of 14% at 12 months and 
25% at 24 months has been reported.2,3   Bisphosphonates could 
also be responsible for delayed fracture healing with delayed 
or absent healing being reported in 39% of cases.1,3,8  Complete 
fractures are known to heal by endochondral ossification of 
cartilage callus.  Although bisphosphonates do not interfere with 
this aspect of the healing process, their negative effect on bone 
remodelling delays fracture consolidation and development of 
mature bone.  Incomplete fractures, on the other hand, heal 
by bone remodelling and their healing is therefore delayed by 
bisphosphonates treatment.  Bisphosphonates are also thought 
to have an inhibitory effect on angiogenesis which in turn 
may have a negative effect on fracture healing.3  It is therefore 
crucial to aim at preventing these fractures from happening, 
where possible, and manage them effectively both medically 
and surgically.
Similar to treatment of any other disease, the decision to 
start patients on bisphosphonates therapy for their osteoporosis 
should be taken based on the known advantages and potential 
risks.  It is not possible to have one management protocol in 
place to cover all clinical scenarios, and clinical expertise and 
judgement should be used.  FRAX, the WHO population-specific 
Fracture Risk Assessment Tool (www.sheffield.ac.uk/FRAX/) 
could be used to evaluate risk.1  
The current general opinion regarding medical treatment 
is as follows:
• Patients with a low risk of developing osteoporosis-
related insufficiency fractures should not be started 
on bisphosphonates.  In the United States, guidelines 
suggest treating any patient with a 10 year major 
osteoporotic risk of >20% or a hip fracture risk of >3%.9
• Those with spinal osteoporosis but normal or near 
normal hip bone mineral density (BMD) should be 
considered for alternative treatments.3    
• Bisphosphonate treatment is known to be effective in 
reducing risk of insufficiency fractures for at least 5 
years.   Continuation of therapy beyond this time may be 
necessary based on estimated fracture risk.  It is however 
uncertain if risk reduction will continue beyond the first 
5 years and continuation of therapy beyond this point 
warrants an annual reassessment. 2,3,9,10,11   
• Suspending treatment for 1 year or more should be 
considered in patients with a low fracture risk, with 
no history of insufficiency fractures and a T-score of 
more than -2.0 to -2.5.2,3,9,10,11   There is no generalised 
agreement as to whether this is of proven benefit.  
Currently, there are also no guidelines in place indicating 
if and when bisphosphonates should be restarted 
following a ‘drug holiday’, but due consideration to 
restarting should be given if fracture risk increases.  
• There is however a strong favoured opinion that 
bisphosphonates should be discontinued in patients 
with incomplete or complete atypical fractures and that 
adequate calcium and vitamin D supplementation should 
be considered.  
• Although the use of teripartide (recombinant parathyroid 
hormone) in these patients has been claimed to aid 
fracture healing by increasing bone turnover, no solid 
clinical evidence exists to substantiate this.  It should 
however be considered in situations of fracture non-
union.1,2,3 
There is, as yet, no agreed surgical management protocol 
for these fractures.  It is however agreed that where orthopaedic 
intervention is required full-length intramedullary nail 
reconstruction is the method of choice as it allows endochondral 
fracture repair which is not inhibited by bisphosphonates.1,3,4 
Locking plates are, on the other hand not recommended as 
they do not allow endochondral healing and have a high risk of 
non-union.3,4  The general opinion is as follows:
• Complete atypical fractures need to be stabilised by 
intramedullary nailing.
• Prophylactic intramedullary nailing is advised for 
patients with incomplete fractures in the presence of 
prodromal pain. 1,3    
• In the absence of pain, a 2 to 3 month period of 
conservative partial-weight-bearing should be attempted, 
with prophylactic nailing considered if patients become 
symptomatic.  If conservative treatment is successful, 
reduced activity should be enforced until no residual 
oedema is seen on MRI.1,3  
The risk of a second complete fracture of the contralateral 
femur is high as shown in our case.  The management of 
the contralateral femur following an initial atypical fracture 
has not been analysed in depth.  There are four potential 
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management plans. The contralateral hip should be imaged 
by plain radiography in the first instance.   The options for 
prophylactic intramedullary nailing of the contralateral femur 
are then as follows:
• Operate ONLY when patient is symptomatic AND either 
plain radiography or isotope bone scan is abnormal.  
• Operate when patient is symptomatic even if imaging is 
normal.
• Operate when imaging is abnormal even if patient is 
asymptomatic.
• Prophylactically nail the contralateral femur at the 
same surgical sitting as the initial emergency nailing 
independent of symptoms or imaging findings. 
As clearly seen in our case, the contralateral femoral changes 
progressed very rapidly following the initial injury.  The reason 
for this rapid change is thought to be the markedly increased 
mechanical strain placed onto the uninjured lower limb during 
the postoperative recovery.  It must be remembered that the 
effects of bisphosphonates on bone are systemic and that the 
contralateral femur must also be thought of as inherently weak. 
The widely accepted orthopaedic surgical protocol used in the 
management of unilateral slipped upper femoral epiphysis 
(SUFE), which is known to occur bilaterally in a third of patients, 
should be borne in mind when formulating a management 
protocol for patients presenting with their first episode of 
atypical fractures.  In view of the 28% risk of bilateral fractures 
and the increased morbidity and mortality associated with 
these fractures, it is our belief that following detailed discussion 
informing patients of the advantages and risks carried by the 
available options, prophylactic nailing of the contralateral 
femur at the same time as emergency nailing of the presenting 
fractured femur is probably the most advantageous. 
Conclusion
Bisphosphonates have been shown to reduce the risk of 
insufficiency fractures of the hip and spine in post-menopausal, 
osteoporotic females.  Several reports suggest a relationship 
between long-term use of bisphosphonates and the development 
‘atypical’ subtrochanteric and femoral diaphyseal fracture.  The 
definitive causal relationship is, however, yet to be proven and 
more research projects are urgently needed.  Early diagnosis and 
appropriate management of these ‘atypical‘ fractures, as well as 
exclusion of bilateral disease, is of paramount importance since 
it may reduce the morbidity and mortality risk associated with 
‘complete‘ fractures.
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